Podcasts about agtc

Dr. Chanfeng Zhao is the VP of R&D Chemistry at TriLink BioTechnologies. She has over 25 years of experience in nucleotide and modified nucleotide chemistry for sequencing and genomics applications. She co-founded MyChem LLC, a company later acquired by TriLink, specializing in ultra-pure synthetic nucleotides. Chanfeng was the CSO and Co-founder of Sequlite Genomic (acquired by Fapon International), a company that was developing NGS instruments and reagents. Previously, Dr. Zhao was one of the first employees at Illumina, where she developed oligonucleotide attachment chemistry for BeadChip products. She holds a Ph.D. in Chemistry from SUNY Buffalo and a B.Sc. in Petroleum Chemical Engineering. Dr. Zhao is an inventor on over 20 issued patents.What do we talk about in this episode?What are nucleotides & genomes?The difference between chemistry and chemical engineering.Chanfeng's career path from chemical engineering to chemistry. Working at startups, starting her own company, and selling that company.Her experience coming to the US and raising a son while going to grad school.How her curiosity fuels her passion for science.Music used in the podcast: Higher Up, Silverman Sound StudioYou can support my podcast on Patreon here: https://patreon.com/user?u=72701887ResourcesGenomics is an interdisciplinary field of biology focusing on the structure, function, evolution, mapping, and editing of genomes. A genome is an organism's complete set of DNA, including all of its genes as well as its hierarchical, three-dimensional structural configuration. (Wikipedia)Nucleotides are organic molecules composed of a nitrogenous base, a pentose sugar and a phosphate. They serve as monomeric units of the nucleic acid polymers – deoxyribonucleic acid and ribonucleic acid, both of which are essential biomolecules within all life-forms on Earth. (Wikipedia)Invisible Women: Data Bias in a World Designed for Men by Caroline Criado Perez.AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. (https://agtc.gcs-web.com)

Beacon Therapeutics has reported vision improvements for five of eight patients receiving the high dose of its X-linked retinitis pigmentosa (XLRP) gene therapy in the Phase 2 SKYLINE clinical trial. Known as AGTC-501, the emerging gene therapy is for patients with mutations in RPGR, the gene most frequently associated with XLRP. Interim, 12-month results for SKYLINE were reported on February 7, 2024, by Mark Pennesi, MD, PhD, director, Ophthalmic Genetics at the Retina Foundation of the Southwest, at the 47th Macula Society Meeting.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FHQ865. CME credit will be available until December 15, 2024.Retinal Disease in the ED: “See Me Now”- A Primer for Emergency Physicians on the Recognition and Differential Diagnosis of Retinal Vein OcclusionsThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.DisclosuresRobert M. Hughes, DO, has no financial interests/relationships or affiliations in relation to this activity.Christina Y. Weng, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alcon; Allergan/AbbVie Inc.; Alimera Sciences; Apellis Pharmaceuticals; Dutch Ophthalmic Research Center (DORC); EyePoint Pharmaceuticals, Inc.; Genentech, Inc.; IVERIC bio, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and REGENXBIO.Grant/Research Support from AGTC; Alimera Sciences; and DRCR Retina Network.Other Financial or Material Support in the form of royalties from Springer Publishers.Medical DirectorKristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FHQ865. CME credit will be available until December 15, 2024.Retinal Disease in the ED: “See Me Now”- A Primer for Emergency Physicians on the Recognition and Differential Diagnosis of Retinal Vein OcclusionsThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.DisclosuresRobert M. Hughes, DO, has no financial interests/relationships or affiliations in relation to this activity.Christina Y. Weng, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alcon; Allergan/AbbVie Inc.; Alimera Sciences; Apellis Pharmaceuticals; Dutch Ophthalmic Research Center (DORC); EyePoint Pharmaceuticals, Inc.; Genentech, Inc.; IVERIC bio, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and REGENXBIO.Grant/Research Support from AGTC; Alimera Sciences; and DRCR Retina Network.Other Financial or Material Support in the form of royalties from Springer Publishers.Medical DirectorKristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

January 6, 2023. For the first Eye on the Cure episode for 2023, host Ben Shaberman highlights some of the promising clinical advancement made in therapy development over the last year. His recap includes discussions of emerging treatments from: SparingVision, Atsena Therapeutics, Alkeus, Belite, Apellis, Iveric Bio, MeiraGTx, AGTC, 4DMT, and Opus Genetics, which, after the recording of the episode, reported its acquisition of rights to gene therapies for Best disease and RP (RHO).

We discuss new developments in gene therapy for inherited retinal diseases with Sue Washer, President and CEO of AGTC.

Transportation/Logistics Update ABC staff attended the Agriculture Transportation Coalition (AgTC) annual conference in Tacoma that focused on ongoing transportation disruptions and touched on many aspects of the logistics crisis. Numerous discussions focused on how and when things may begin to improve; the consensus among those presenting was that things will continue to improve throughout the calendar year with something like a return to normalcy being realized in 2023. Carrier rates, however, are expected to continue to be significantly higher than their historical average. While things continue to improve, there was also much discussion regarding the Ocean Shipping Reform Act (OSRA) which was recently signed into law. While formulation of exact regulations for carriers will be ongoing through the year, many of the law's provisions immediately went into effect, including those requiring carriers to provide justification for detention and demurrage fees, as well as the provision barring carriers from unreasonably declining cargo bookings. For more information, contact bdensel@almondboard.com. New Bill Proposes Port Priorities for Exports The American Port Access Privileges Act (H.R. 8243, introduced June 29 by Rep. Garamendi, D-Calif.) would build on OSRA by encouraging ocean carriers to ship U.S. exports to foreign markets. ABC will be evaluating the legislation and working with our partners at AgTC to ensure they have any information needed to assist almond exporters. According to information from Garamendi's office, this bill would: reward ocean carriers that serve multiple ports in the U.S. or with significant cargo bookings of U.S. exports (i.e., those accounting for at least 51 percent of the vessel's carrying capacity by weight or container volume) by moving those vessels to the front of the queue for unloading and loading; require export-carrying vessels seeking preferential berthing to report cargo bookings at least seven days in advance to port operators; authorize the Department of Transportation to collect data on berthing and cargo practices at U.S. ports to evaluate carriers' practices for port calls and cargo bookings and the impact of preferential berthing; and codify current preferences for military, Jones Act, and other U.S.-flagged vessels in place at many major U.S. ports. Update on China's Decree 248 ABC staff continues to work with U.S. Food and Drug Administration (FDA) in finding ways to finalize facility registrations initially fast-tracked by General Administration of Customs of the People's Republic of China (GACC) back in December. It's still not clear how FDA and GACC will sort out the review and approval of registrations submitted more recently including the addition of products that were not requested in the initial registrations. The United States Agricultural Trade Office (ATO) based in Guangzhou, China, held a webinar on July 6 featuring GACC experts on self-registration for those products that don't require support from the competent authority. Although these facilities do not require assistance from FDA, much of the documentation required is the same such as production process flowcharts, signed enterprise statements, and the proposed “licensed production certificate (business license?)” requirement. ABC is working with FDA and USDA/China to address many of these outstanding issues. If you have questions about the registration process, please contact kschneller@almondboard.com.

Straight from Benzinga newsdesk, hosts Brent Slava and Steve Krause bring you the market news and stocks to watch.Today's 5 Stock Ideas:Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Mar. 22, 2022: BABA, OKTA, DPRO, AGTC, ADBEToday's 5 Stock Ideas:Alibaba (BABA) - Shares up ~10% premarket. The company raised its buyback program from $15 billion to $25 billion.Okta (OKTA) - Shares down ~8% premarket. A report indicated the company is investigating a report of a digital breach after hackers posted screenshots of what they claimed were its internal company environment.Draganfly (DPRO) - Shares up ~85% premarket. The company announced it received an order for its Medical Response and Search and Rescue Drones from Coldchain Delivery Systems for immediate deployment with Revived Soldiers Ukraine.Applied Genetic Technologies (AGTC) - Shares down ~30% premarket. The company announced a common stock offering.Hosts:Steve Krause Reach out to Steve at stevekrause@benzinga.comSr. Reporter Benzinga NewsdeskBrent Slava Reach out to Brent at brent@benzinga.comSr. Reporter, Head of Benzinga Newsdeskpro.benzinga.comFree 2-week trial, no credit card requiredUse coupon code YOUTUBE20 to get 20% offDisclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisionsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

November 5, 2021. Ben Shaberman talks with Dave Knop, PhD, vice president of process development at AGTC, about how emerging gene therapies for inherited retinal diseases are manufactured for use in human studies.

In this episode, Sue Washer, BS, MBA, discusses gene therapy in ophthalmology, ATGC's clinical trial progress, as well as current and future challenges faced by both the cell therapy industry and ophthalmology. Welcome to another exciting episode of Eye Care insider :13 About Washer 1:51 Can you discuss what is gene therapy? How does it work on a basic level? 4:53 How do companies like AGTC make gene therapy work for diseases that may not affect as many people but still make it financially successful for investors? 7:11 Could you talk about where you are in the X-Linked Retinitis Pigmentosa candidate trials? 11:08 Is there an estimated timeline that you have for initial data read out? 14:56 You have another candidate for achromatopsia … I was reading you had some new data released. Could you go into more details about that? 16:23 What do you think is the most important topic or challenge you see facing the gene therapy industry and ophthalmology today and in the future? 20:56 Thank you so much for your insight into this fascinating topic 23:22 How to find out more about AGTC 23:31 Thank you for listening 24:15 Sue Washer, BS, MBA is the president and chief executive officer of AGTC. We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact AGTC through the company's website at www.atgc.com. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Washer is the president and CEO of AGTC.

July 2, 2021. Jill Dolgin, the executive director of patient advocacy at AGTC, talks to Ben about her role in helping patients understand clinical research. They also discuss AGTC's current gene therapy clinical trials for X-linked retinitis pigmentosa and achromatopsia.

News | AGTC Reports Encouraging Results from Phase 1/2 Gene Therapy Clinical Trial for Achromatopsia by Foundation Fighting Blindness

The company is planning the launch of a Phase 2/3 trial for its XLRP gene therapy

Dr. Paul Yang, of Casey Eye Institute, joins to discuss new ARVO 2021 data supporting the gene therapy for X-linked retinitis pigmentosa.

Featuring AGTC BHAT BLCT BNGO BTBT CAN CCIV CCL CCO CEVA CLDR GCI GROW JETS LAC LKCO MARA OSS PAVM PINS PRTS RIOT RWLK SCKT SHIP SOS TDOC TRIB UPWK Trading Risk Disclaimer All the information shared in this video is provided for educational purposes only. Any trades placed upon reliance of SharperTrades.com are taken at your own risk for your own account. Past performance is no guarantee. While there is great potential for reward trading stocks, commodities, options and forex, there is also substantial risk of loss. All trading operations involve high risks of losing your entire investment. You must therefore decide your own suitability to trade. Trading results can never be guaranteed. This is not an offer to buy or sell stocks, forex, futures, options, commodity interests or any other trading security.

The COVID-19 pandemic continues to disrupt biopharma clinical trials, especially those conducted with at-risk patient populations. From patient recruitment to data collection, clinical trials execution became considerably more challenging in 2020. On this episode of The Business Of Biotech, AGTC CEO Sue Washer gives us a behind-the-scenes look at the creative measures her company took to serve a geographically dispersed clinical patient population and ensure her company met clinical milestones.

This episode features Sue Washer, CEO of Applied Genetic Technologies Corporation (AGTC). Here, she discusses her career journey, trends she’s seeing in the biotech industry, and more.

Prior to joining AsclepiX Therapeutics, Dr. Heah served as Chief Medical Officer at Applied Genetic Technologies Corporation (AGTC), where she worked on developing ophthalmic gene therapies. Before her tenure at AGTC, Dr. Heah was Vice President, Global Head of Clinical Research, Medical and Professional Affairs at Aerie Pharmaceuticals, where she played a key role in driving growth and success of the organization globally. In this position, Dr. Heah was responsible for global strategy and development of ophthalmology programs, leading an experienced team executing clinical research, clinical operations, medical affairs, and professional affairs. During her tenure, she successfully expanded her global team size from 10 to 52 professionals and took a leading role in Aerie’s pharmaceutical development program for milestone product candidates, including Rhopressa® and Rocklatan®.Prior to her tenure at Aerie, Dr. Heah served with increasing responsibility, initially as the Director, Senior Global Medical Affairs Physician lead in the worldwide launch of EYLEA® followed by the role of Global Strategic Marketing Director at Bayer Healthcare Pharmaceuticals, where she served as the brand plan lead for EYLEA, an anti-VEGF compound indicated for the management of 5 retinal diseases. As part of her work on EYLEA, Dr. Heah oversaw the development of brand strategy, positioning, market research, advisory boards, key message development, pricing & reimbursement, and promotional campaigns. While at Bayer, her product portfolio’s value exceeded €1B annually. Dr. Heah has clinical experience as an ophthalmologist in the U.K. Dr. Heah earned her Doctorate of Medicine from Guy’s Kings and St. Thomas’ School of Medicine, King’s College, University of London, and her Executive Master’s in Business Administration from the European School of Management & Technology (ESMT), Berlin.

AGTC is developing gene therapies to treat patients with rare inherited eye conditions. It has multiple programs it is advancing to restore visual function in patients with diseases that threaten to leave them blind. One issue that has emerged, though, is finding the right measures and endpoint for its clinical studies and getting the U.S. Food and Drug Administration to recognize the traditional endpoints and measures used for eye diseases may not be well suited for all of these conditions. We spoke to Sue Washer, CEO of AGTC, about the company, the indications it is pursuing, and its efforts to find and use more appropriate endpoints for its studies.

Together, Roche and Biogen paid over $5.5 billion for gene therapy companies Spark and Nightstar. What does this mean for the emerging technology? Spark, of course, received FDA approval for Luxturna as a treatment for inherited retinal disease. But the drug isn’t Roche’s primary focus. Meanwhile, Nightstar’s clinical-stage products could give Biogen a second shot at a gene therapy portfolio after the company severed ties with AGTC in December. Could Biogen make a move to bulk up its ophthalmology offerings?

Latest updates on AGTC Gene Therapy

Latest updates on AGTC Gene Therapy

Sue Washer, AGTC president and CEO, has joined the board of directors of the Biotechnology Innovation Organization (BIO). In this podcast, she talks about how she'll fulfill her duties for the biotech advocacy organization.

In July, Biogen signed a potential $1 billion-plus deal with Applied Genetic Technologies Corp. The deal, which included an equity investment, centered around AGTC’s leading gene therapy programs developing treatments for rare ophthalmic conditions X -Linked Retinoschisis (XLRS) and X-linked Retinitis Pigmentosa (XLRP). In this podcast, Josh Mandel-Brehm, Director, Business Development and M&A at Bio-gen,discusses how Biogen and AGTC spoke for over a year before the deal came together. Calling the eye, “the window into the brain,” Mandel-Brehm says neurology-focused Biogen might be looking to find new partners in the future.